EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutations [1].